A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

Exclusion Criteria

• •Pustules are limited to psoriasis vulgaris on psoriasis plaques;
• •Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;
• •Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator:
• •Serum virological abnormalities during the screening period;
• •Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;
• •History of serious infection leading to hospitalization within 2 months prior to baseline;
• •Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment;
• •History of opportunistic infection within 6 months prior to baseline;
• •Received live (attenuated) vaccine treatment within 12 weeks prior to baseline;
• •Any major surgery within 4 weeks prior to baseline or planned major surgery during the study;
• •Received blood transfusion within 4 weeks prior to baseline;
• •Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline;
• •Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status;
• •Subjects with any type of active malignancy or a history of malignancy;
• •Alcohol, drug and known drug dependence;
• •Pregnant or lactating women;
• •Subjects cannot tolerate intravenous infusion administration.